*Seminar Series: SCMB Seminar
*Location: AIBN Seminar Room
*Date: 26/07/2017
*Time: 12:00

Speaker #1 details
*Title of talk: Why) is immune memory to pertussis failing and what can we do about it?
*Speaker's name: Dimitri A. Diavatopoulos
*Speaker's organisation: Radboud Center for Infectious Diseases, Radboud university
Speaker's city/state/country: The Netherlands
Talk Abstract: Despite the availability of effective prophylactic vaccines against pertussis, there has been a rise in the incidence of pertussis, with recent epidemics occurring in the last decades in Europe, the US and Australia. As well as being a particular problem in vulnerable infants, with devastating consequences in developing countries, the incidence of pertussis is also increasing in adolescents and adults, particularly in high-income countries. Evidence suggests that immunity in humans wanes rapidly after primary immunization with pertussis vaccines, especially with the acellular pertussis vaccines (aPs) predominantly used in high-income countries. This suggests that the improvements in the safety profile of aPs, as compared to whole cell pertussis vaccines (wPs), may be accompanied by differences in the elicited immune response and a reduction in long-term effectiveness. Changes have also been observed in circulating Bordetella pertussis strains, culminating in the recent emergence and expansion of vaccine antigen-deficient strains, in particular pertactin-deficient strains.

Studies in the recently established baboon model have demonstrated that aPs prevent severe disease but do not prevent asymptomatic infection, i.e. colonization, or transmission to naive animals, whereas infection and to some extent wPs can prevent colonization and transmission and disease. Although a role of functional antibodies and T cell responses in protection against disease and/or carriage has been demonstrated, there are still important knowledge gaps, in particular relating to human immunity to B. pertussis and whether observations in animal models translate to clinical practice. This paucity of knowledge hampers the development and registration of improved vaccines and the design of better vaccination strategies against pertussis in infants, adolescents and adults. The development and licensing of the next generation of improved vaccines depends on 1) a more thorough understanding of immune response to infection 2) identification of immunological correlates of protection and 3) the development of human and animal models as well as bioassays to predict and evaluate vaccine efficacy.
Speaker's bio:

Speaker #2 details
*Title of talk:
*Speaker's name:
*Speaker's organisation:
Speaker's city/state/country:
Talk Abstract:
Speaker's bio:

Other Details:
*Host name: Nick West
Host phone number:
*Host email: n.west@uq.edu.au